Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China

Overview

The present study is a prospective cohort study aiming to improve the clinical capacity in the diagnosis and natural history of Chinese patients with myasthenia gravis (MG). 300 MG patients are planned to recruit, document and prospectively follow up. Management of screening test and cohort manifestation are studied.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2028

Interventions

  • Device: pheripheral biomarkers
    • Detect the pheripheral biomarkers,including lymphocytes and cytokines, in this prospective MG cohort.

Arms, Groups and Cohorts

  • myasthenia gravis
    • 300 MG patients are anticipated for precision diagnosis and disease monitoring.

Clinical Trial Outcome Measures

Primary Measures

  • Myasthenia gravis foundation of America post intervention status
    • Time Frame: 3 years
    • Myasthenia gravis foundation of America post intervention status (PIS) is assessed by the investigators during follow up. According to history inquiry and physical examination, participants are rated as clinical remission (no complain of myasthenia, no weakness at physical examination, and no therapies concerning MG for one year), pharmocological remission (no complain of myasthenia, no weakness at physical examination, but undertaking MG therapies at the last year), minimal manifestation (no complain of weakness, but showing weakness at physical examination), improvement (symptoms and signs), unchanged (symptoms and signs) , worsening(symptoms and signs), exacerbation(symptoms and signs), and death (medical record).

Secondary Measures

  • Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scores at the follow up
    • Time Frame: Baseline, 1 year, 2 year, and 3 year
    • A quantitative MG scoring system (QMG Score) is essential in the objective evaluation of therapy for MG.This scoring system is based on quantitative testing of sentinel muscle groups. Total QMG score range from 0 (extreme disease severity) to 39 (none), higher score indicated less disease severity.
  • Change From Baseline in Manual Muscle Testing (MMT) Scores at the follow up
    • Time Frame: Baseline, 1 year, 2 year, and 3 year
    • The MMT score is the sum of strength or function values assigned by the examining physician to 30 muscle groups usually affected by MG. Total MMT score range from 0 (none) to 124 (extreme muscle weakness), higher score indicated more disease severity.
  • Change From Baseline in Myasthenia Gravis-Quality of Life Questionnaire-15 item (MG-QOL15) Scores at the follow up
    • Time Frame: Baseline, 1 year, 2 year, and 3 year
    • The MG-QOL15 is helpful in informing the clinician about the patient’s perception of the extent of and dissatisfaction with MG-related dysfunction. Total MG-QOL15 score range from 0 (none) to 60 (extreme disease severity), higher score indicated more disease severity.

Participating in This Clinical Trial

Inclusion Criteria

  • fluctuating muscle weakness and fatigability, along with one of the below: – more than 10% amplitude decrement in low frequency repetitive nerve stimulation,less than 10% amplitude increment in high frequency repetitive nerve stimulation; – anti-AChR or MuSK antibody positivity; – positive to the neostigmine test; – understanding and assigning the informed consent form, and having a good compliance with the follow up. Exclusion Criteria:

  • excluding the possible diagnosis of Lambert-Eaton syndrome, congenital myasthenia syndrome,botulism injection, chronic progressive extraocular ophthalmoplegia, etc; – participating other clinical trials; – poor compliance to the follow up.

Gender Eligibility: All

Minimum Age: 0 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Huashan Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Chongbo Zhao, Professor – Huashan Hospital
  • Overall Official(s)
    • Chongbo Zhao, MD, Study Chair, Huashan Hospital, Shanghai,China
  • Overall Contact(s)
    • Chongbo Zhao, MD, 86-021-52889999, zhao_chongbo@fudan.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.